Sayan, MuratGündüz, AlperErsöz, G.İnan, AsumanDeveci, AydınGünal, ÖzgürSargın, FatmaKaragöz, Gülİnci, Ayşeİnan, DilaraUlcay, AsımKaraoğlan, İlkayKaya, S.Kutlu, Selda S.Süer, KayaÇağatay, Atahan2022-12-202022-12-202016Sayan, M. vd. (2016). "Integrase strand transfer inhibitors (INSTIs) resistance mutations in HIV-1 infected Turkish patients". HIV Clinical Trials, 17(3), 109-113.1528-43361945-5771https://doi.org/10.1080/15284336.2016.1153303https://www.tandfonline.com/doi/full/10.1080/15284336.2016.1153303http://hdl.handle.net/11452/29983Objectives: Integrase strand transfer inhibitor (INSTI) is a new class of antiretroviral (ARV) drugs designed to block the action of the integrase viral enzyme, which is responsible for insertation of the HIV-1 genome into the host DNA. The aim of this study was to evaluate for the first time INSTI resistance mutations in Turkish patients. Methods: This study was conducted in Turkey, between April 2013 and April 2015 using 169 HIV-1-infected patients (78 ARV naive patients and 91 ARV-experienced patients). Laboratory and clinical characteristics of ARV naive and ARV-experienced patients were as follows: gender (M/F): 71/7 and 80/11, median age: 38 and 38.4; median CD4+ T-cell: 236 and 216 cells/mm3, median HIV-1 RNA: 4.95+ E5 and 1.08E+ 6 copies/ml. Population-based seqeunces of the reverse transcriptase, protease, and integrase domains of the HIV-1 pol gene were used to detect HIV-1 drug resistance mutations. Result: INSTI resistance mutations were not found in recently diagnosed HIV-1-infected patients. However, ARV-experienced patients had major resistance mutations associated with raltegravir and elvitegravir; the following results were generated: F121Y, Y143R, Q148R and E157Q (6/91 - 6.6%). Conclusions: The prevalence of INSTI resistant mutations in ART-experienced patients suggested that resistance testing must be incorporated as an integral part of HIV management with INSTI therapies.eninfo:eu-repo/semantics/closedAccessInfectious diseasesPharmacology & pharmacyHiv-1 integraseIntegrase inhibitorsRaltegravirElvitegravirDolutegravirDrugResistanceDna sequencingAntiretroviral-naive patientsNatural polymorphismsHIV-1IndividualsTherapyUpdateTurkeyAdultAgedAmino acid substitutionCD4 lymphocyte countCodonCoinfectionDrug resistance, viralFemaleGenotypeHIV infectionsHIV integrase inhibitorsHIV-1HumansMaleMicrobial sensitivity testsMiddle agedMutationRisk factorsRNA, viralTurkeyViral loadYoung adultArticle0003751262000032-s2.0-8497863056410911317327125365Infectious diseasesPharmacology & pharmacyIntegrase Inhibitors; Lens Epithelium-Derived Growth Factor; Human Immunodeficiency Virus 1Anti human immunodeficiency virus agentElvitegravirIntegraseIntegrase strand transfer inhibitorProteinaseRaltegravirRNA directed DNA polymeraseUnclassified drugVirus RNACodonIntegrase inhibitorAdultArticleCD4+ T lymphocyteCytomegalovirus infectionDelta agent hepatitisFemaleHepatitis BHepatitis CHumanHuman immunodeficiency virus 1Human immunodeficiency virus 1 infectionHuman immunodeficiency virus infected patientLung tuberculosisMajor clinical studyMaleMixed infectionPriority journalPseudomonas pneumoniaStructural geneThrushToxoplasmosisTurkish citizenVirus detectionVirus mutationAgedAmino acid substitutionAntiviral resistanceCD4 lymphocyte countCodonDrug effectsGeneticsGenotypeHIV InfectionsMicrobial sensitivity testMiddle agedMutationRisk factorTransmissionTurkeyVirologyVirus loadYoung adult